Soleno Therapeutics announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K (ATP) Channel Activators for the Treatment of Rare Diseases.

Written By Guest User

by: Soleno Therapeutics

Guest User
Previous

Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics
Next

Discovery shows how to treat heart attacks; drug development underway